Welcome to our dedicated page for Evofem Bioscienc news (Ticker: EVFM), a resource for investors and traders seeking the latest updates and insights on Evofem Bioscienc stock.
Evofem Biosciences, Inc. (OTC: EVFM) regularly issues news and updates focused on women’s sexual and reproductive health, its FDA-approved products, and its corporate strategy. Company press releases highlight developments around PHEXXI, a hormone-free, on-demand prescription contraceptive vaginal gel, and SOLOSEC, a single-dose oral antimicrobial treatment for bacterial vaginosis and trichomoniasis.
News items cover a range of topics, including quarterly and annual financial results, cost-of-goods initiatives, and progress on international expansion. For example, Evofem has announced licensing arrangements with Pharma 1 Drug Store in the Middle East and North Africa, regulatory submissions for PHEXXI and SOLOSEC in the United Arab Emirates, and steps toward commercialization in Gulf Cooperation Council states. These updates provide context on how the company is seeking to diversify and expand its revenue stream beyond the United States.
Evofem’s releases also describe marketing and educational campaigns such as the "Say Vagina" initiative, which the company presents as an effort to normalize clinical language and address stigma around vaginal health. Other news has detailed the impact of social media campaigns on traffic to the PHEXXI website, engagement from healthcare providers, and broader brand awareness.
In addition, investors can find news about corporate actions and governance, including information on a previously proposed merger with Aditxt, Inc. and its subsequent termination, reverse stock split authorization, and capital raises through notes and warrants. This news page aggregates such announcements so readers can follow product, regulatory, commercial, and corporate developments related to Evofem Biosciences and its EVFM stock symbol over time.
Evofem (OTCID: EVFM) announced that CEO Saundra Pelletier’s keynote, “Rebuilding Women’s Health from the Ground Up,” from Fierce JPM Week 2026 is available on demand. Pelletier called for a “ground-up reset” of women’s health, criticized exclusionary legacy clinical practices, and outlined Evofem’s emphasis on transparency, education, and respect in product development and leadership.
Fierce Pharma offers free on-demand access; attendees can register, log in, and select the Friday, January 23 session at 9:25–9:50am to view.
Evofem Biosciences (OTCID: EVFM) announced on January 21, 2026 the launch of the Say Vagina Store, expanding its Say Vagina campaign to normalize accurate female anatomical language and advance education and autonomy in women’s health.
The store is positioned as an extension of the campaign’s advocacy and educational work addressing perceived censorship and algorithmic suppression of clinical terms, and will support awareness, dialogue, and cultural change. The campaign will be further highlighted at a featured SXSW 2026 panel on platform censorship and algorithm impacts on women’s health. The store is available at www.SayVaginaStore.com.
Evofem Biosciences (OTCID: EVFM) announced that the Emirates Drug Establishment (EDE) issued favorable pricing certificates for PHEXX on Nov 21, 2025, a preliminary administrative step toward UAE regulatory approval.
Pharma 1, Evofem's licensee, holds exclusive commercialization rights for PHEXX and SOLOSEC in six GCC states with potential expansion into 15 MENA countries, and is expected to launch PHEXX in the UAE in 2026, subject to timely EDE marketing approval and other regulatory and commercial conditions. Pharma 1 will manage distribution, sales, marketing, and pharmacovigilance in the licensed territory.
Evofem (OTCID: EVFM) reported Q3 2025 results: net sales $5.0M (up 10% vs. prior-year quarter) and operating income $1.0M versus a $2.4M operating loss a year earlier. Total operating expenses fell to $4.0M, a 42% decline driven by a $1.0M decrease in G&A and a $1.9M one-time accounting gain tied to an expired Rush patent contingent royalty.
The company reported a net loss attributable to common stockholders of $1.7M (loss per share $0.01) vs. $2.4M ($0.02) in Q3 2024. Liquidity included $0.8M restricted cash at September 30, 2025. Corporate and commercial updates: submitted SOLOSEC for UAE approval, ongoing NIH-funded Phase 4 trial for SOLOSEC vs metronidazole, terminated the proposed merger with Aditxt, and advanced manufacturing cost reductions of ~50% for PHEXX and SOLOSEC.
Evofem Biosciences (OTCID: EVFM) announced on October 20, 2025 that its stockholders did not approve the Amended and Restated Merger Agreement with Aditxt (NASDAQ: ADTX), and Evofem has exercised its rights to terminate the Merger Agreement.
The company said it will pivot to regain a national listing for its stock and secure growth capital to catalyze net sales while targeting sustainable positive EBITDA in 2027. Evofem noted a continuing collaboration with Aditxt to commercialize Mitomic diagnostic tests under their September 2024 agreement.
Evofem commercializes two FDA-approved sexual health products, PHEXXI vaginal gel and SOLOSEC oral granules, and reported 2024 was its fourth consecutive year of net sales growth.
Evofem Biosciences (OTCID: EVFM) announced that its licensee Pharma 1 has submitted SOLOSEC® for marketing approval in the United Arab Emirates (UAE). SOLOSEC® is a single-dose oral treatment FDA-approved for bacterial vaginosis (BV) and trichomoniasis.
Pharma 1, which holds exclusive commercialization rights for SOLOSEC® in the Middle East, targets a 1H 2026 launch in the UAE. The market opportunity is significant, with 25-41% BV prevalence in the MENA region, representing 1.0-1.7 million women in the UAE alone. Additionally, about 4.7% of women in the general MENA population are affected by trichomoniasis.
This marks SOLOSEC's first ex-U.S. regulatory filing, representing a strategic move to expand and diversify Evofem's revenue stream.
Evofem Biosciences (OTCID: EVFM) commemorates World Contraception Day by highlighting its commitment to women's reproductive health innovation. The company's flagship products include PHEXXI®, the first hormone-free, on-demand contraceptive vaginal gel, and SOLOSEC®, a single-dose treatment for bacterial vaginosis and trichomoniasis.
CEO Saundra Pelletier emphasizes the importance of providing women with flexible contraceptive options, particularly for those who want alternatives to hormonal birth control. The company's "Say Vagina" awareness campaign has reached millions, focusing on destigmatizing women's health conversations and improving health education.
Evofem Biosciences (OTCID: EVFM) reported significant success from its August 2025 "Say Vagina" campaign, designed to normalize clinical anatomical language. The campaign generated over 2.5 million views across social media platforms and drove a 130% increase in traffic to PHEXXI.com, the company's hormone-free contraceptive product website.
Key achievements include PHEXXI becoming the #1 most followed contraceptive brand among healthcare providers, and CEO Saundra Pelletier's Instagram reach growing by 400%. The company plans to launch SayVaginaStore.com in September, with all proceeds from campaign merchandise being donated to selected sexual and reproductive health charities.
Evofem Biosciences (OTCID: EVFM) expects approval of its merger with Aditxt (Nasdaq: ADTX) at the upcoming Special Meeting of Stockholders on September 26, 2025. The company has secured support agreements from Series E-1 and G-1 holders, representing 53.71% of combined voting power, sufficient for merger approval.
Under the agreement, Evofem will become a wholly-owned subsidiary of Aditxt, forming the core of their women's health program. As of August 26, 2025, Evofem had 118,656,354 shares of common stock outstanding, with Series E-1 and G-1 holders controlling 13.87% and 39.84% of voting power, respectively.
Evofem Biosciences (OTCID: EVFM) announced that Illinois has passed House Bill 3489, allowing pharmacists to prescribe non-hormonal and emergency contraceptives, including PHEXXI®, effective January 1, 2026.
The legislation positions Illinois alongside 30 other states and DC in permitting pharmacist-prescribed contraceptives. PHEXXI, FDA-approved in May 2020, is a hormone-free vaginal gel contraceptive that can be used regardless of BMI and showed increased sexual satisfaction in clinical trials.
The law, introduced by Representative Michelle Mussman and sponsored by Senator Rachael Ventura, aims to expand contraceptive access and choices for Illinois residents.
FAQ
What is the current stock price of Evofem Bioscienc (EVFM)?
What is the market cap of Evofem Bioscienc (EVFM)?
